Sildenafil and Female Sexual Dysfunction: Isn’t It Time to Target the Right Candidates?

Abstract

Female sexual arousal disorder (FSAD) is one of the subcategories of female sexual dysfunction (FSD). During recent years, many different chemical and herbal medicines have been introduced to the market by pharmaceutical companies targeting women who suffer sexual dysfunction. Notwithstanding, the majority of these medications failed to demonstrate their efficacy in experimental studies. Regarding the fact that men and women are increasingly becoming similar in terms of life style, familial and social responsibilities, etc, treating female sexual problems by the use of sildenafil citrate (Viagra) has become of interest to many physicians and professionals. This drug is a phosphodiesterase type 5 inhibitor and is commonly used for the treatment of erectile dysfunction. Evaluation of the effect of sildenafil on FSAD has yielded controversial results and still there is no unanimity on this issue. The focus of this review article is on the efficacy of sildenafil as a treatment for FSAD. Regarding the fact that women's sexual dysfunction is a biopsychosocial disorder with a multifaceted etiology, it is proposed that the sole use of sildenafil may not be an effective treatment for FSAD. All aspects of female sexuality should be taken into account during evaluation of female sexual function and when therapeutic approaches for FSAD are introduced. As a matter of fact, women's sexual problems may become worse and their self-confidence may be negatively affected if improper treatment approach is nominated.